[A23-134] Rucaparib (maintenance treatment in ovarian cancer after first-line therapy) – Benefit assessment according to §35a Social Code Book V
Last updated 15.03.2024
Project no.:
A23-134
Commission:
Commission awarded on 14.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A23-134
| Project no. | Title | Status |
|---|---|---|
| A19-23 | Rucaparib (ovarian, fallopian tube or peritoneal cancer; maintenance treatment) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-22 | Rucaparib (ovarian, fallopian tube or peritoneal cancer; treatment) - Benefit assessment according to §35a Social Code Book V | Commission completed |